These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36692980)

  • 1. State-of-the-art therapy for Down syndrome.
    Lorenzon N; Musoles-Lleó J; Turrisi F; Gomis-González M; De La Torre R; Dierssen M
    Dev Med Child Neurol; 2023 Jul; 65(7):870-884. PubMed ID: 36692980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical Care of Adults With Down Syndrome: A Clinical Guideline.
    Tsou AY; Bulova P; Capone G; Chicoine B; Gelaro B; Harville TO; Martin BA; McGuire DE; McKelvey KD; Peterson M; Tyler C; Wells M; Whitten MS;
    JAMA; 2020 Oct; 324(15):1543-1556. PubMed ID: 33079159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down Syndrome and Alzheimer's Disease: Issues and Implications for Social Work Practice.
    Fredericksen J; Fabbre V
    J Gerontol Soc Work; 2018 Jan; 61(1):4-10. PubMed ID: 29058538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of mouse models to understand and improve cognitive deficits in Down syndrome.
    Das I; Reeves RH
    Dis Model Mech; 2011 Sep; 4(5):596-606. PubMed ID: 21816951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOE ε4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for All.
    Lemere CA; Head E; Holtzman DM
    JAMA Neurol; 2021 Aug; 78(8):913-915. PubMed ID: 34228117
    [No Abstract]   [Full Text] [Related]  

  • 9. Translating molecular advances in Down syndrome and Fragile X syndrome into therapies.
    Faundez V; De Toma I; Bardoni B; Bartesaghi R; Nizetic D; de la Torre R; Cohen Kadosh R; Herault Y; Dierssen M; Potier MC;
    Eur Neuropsychopharmacol; 2018 Jun; 28(6):675-690. PubMed ID: 29887288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?
    Guo SW; Groothuis PG
    Hum Reprod Update; 2018 Sep; 24(5):577-598. PubMed ID: 29893860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal treatment of Down syndrome: a reality?
    Guedj F; Bianchi DW; Delabar JM
    Curr Opin Obstet Gynecol; 2014 Apr; 26(2):92-103. PubMed ID: 24573065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions.
    Nieuwenhuis-Mark RE
    Res Dev Disabil; 2009; 30(5):827-38. PubMed ID: 19269132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.
    Iulita MF; Garzón Chavez D; Klitgaard Christensen M; Valle Tamayo N; Plana-Ripoll O; Rasmussen SA; Roqué Figuls M; Alcolea D; Videla L; Barroeta I; Benejam B; Altuna M; Padilla C; Pegueroles J; Fernandez S; Belbin O; Carmona-Iragui M; Blesa R; Lleó A; Bejanin A; Fortea J
    JAMA Netw Open; 2022 May; 5(5):e2212910. PubMed ID: 35604690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.
    Rueda N; Flórez J; Dierssen M; Martínez-Cué C
    Prog Brain Res; 2020; 251():245-268. PubMed ID: 32057309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for treating Down syndrome require quality of life measurement.
    Goodman MJ; Brixner DI
    Am J Med Genet A; 2013 Apr; 161A(4):639-41. PubMed ID: 23495233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rodent models in Down syndrome research: impact and future opportunities.
    Herault Y; Delabar JM; Fisher EMC; Tybulewicz VLJ; Yu E; Brault V
    Dis Model Mech; 2017 Oct; 10(10):1165-1186. PubMed ID: 28993310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aging With Down Syndrome: The Dual Diagnosis: Alzheimer's Disease and Down Syndrome.
    Cipriani G; Danti S; Carlesi C; Di Fiorino M
    Am J Alzheimers Dis Other Demen; 2018 Jun; 33(4):253-262. PubMed ID: 29504408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine manifestations of Down syndrome.
    Whooten R; Schmitt J; Schwartz A
    Curr Opin Endocrinol Diabetes Obes; 2018 Feb; 25(1):61-66. PubMed ID: 29135488
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.